IL-23/Th17 targeted therapies in SAPHO syndrome. A case series
IL-23/Th17 targeted therapies in SAPHO syndrome. A case series
复制标题
DOI：
10.1016/j.jbspin.2017.05.016
复制
发表时间：
2017-12-01
期刊：
影响因子：
4.2
通讯作者：
Prati, Clement
中科院分区：
文献类型：
--
作者：
Wendling, Daniel;Aubin, Francois;Prati, Clement
SAPHO综合征是一种罕见的实体与皮肤和风湿性炎症表现。治疗不标准，在抗炎药物反应不足的情况下，已报告使用抗TNF或抗IL-1生物治疗。IL-23/Th 17轴可能参与SAPHO综合征的发病。我们报告了6个疗程的IL-23和IL-17靶向治疗（3例优特克单抗和3例阿司奴单抗）对既往治疗（csDMARD和bDMARD）无反应的SAPHO综合征患者的结果。平均治疗持续时间为5.5个月，在3例病例中观察到皮肤症状改善，1例使用阿基诺单抗改善，2例缓解（1例使用阿基诺单抗，1例使用乌司奴单抗）。关于风湿症状，在六个疗程的任何一个疗程下都没有明显的改善。除乌司奴单抗组1例和阿司奴单抗组另1例出现反常银屑病发作外，未报告特殊安全性问题。(C)2017年法国rhumatologie协会。由Elsevier Masson SAS出版。All rights reserved.
SAPHO syndrome is a rare entity with skin and rheumatologic inflammatory presentation. The treatment is not standardized, and in case of inadequate response to anti-inflammatory drugs, the use of anti-TNF or anti-IL-1 biologic treatments has been reported. The IL-23/Th1 7 axis may be involved in SAPHO syndrome. We report the results of six courses of IL-23 and IL-17 targeted therapies (3 ustekinumab and 3 secukinumab) in patients with SAPHO syndrome unresponsive to previous treatments (csDMARDs and bDMARDs). With a mean treatment duration of 5.5 months, improvement of skin symptoms was noticed in three cases, one improvement with secukinumab and two remissions (one with secukinumab, one with ustekinumab). Regarding the rheumatic symptoms, no major improvement was obvious under any of the six treatment courses. No particular safety concerns were reported, except cases of paradoxical psoriasis flare in one under ustekinumab and the other case under secukinumab. (C) 2017 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.